SYKSYK
US • —
$314.84
P/E
36.47
PEG
2.21
FCF Yield
—
Rev Growth YoY
+8.8% YoY
Gross Margin
64.2%
Health Score
8/10
D/E Ratio
0.71
Confidence
LOW
Business Snapshot
Stryker Corporation is a medical technology company focused on orthopaedic implants, surgical equipment, and neurotechnology products. It operates in the global medical devices market, competing as a dominant player alongside Johnson & Johnson and Medtronic in orthopaedics and surgical solutions. The company holds a strong competitive position with established hospital relationships and a broad portfolio spanning joint replacements, trauma products, and robotic-assisted surgical systems. Revenue growth of 8.8% year-over-year and net margins of 13.2% indicate a well-established, large-scale operation generating consistent profitability.
Financial Health
Stryker maintains strong profitability with a gross margin of 64.2% and a net margin of 13.2%, reflecting a high-value product mix typical of the medical technology sector. The balance sheet leans conservative with a debt/equity ratio of 0.71x, suggesting moderate leverage, while the current ratio of 1.89x indicates adequate short-term liquidity to cover liabilities...
Risk Assessment
- VALUATION — P/E of 36.47x trades at a 66% premium to the sector average of 22x, pricing in high future growth expectations.
- VALUATION — Price/Sales of 4.77x and Price/Book of 6.0x further elevate the stock above typical medical device valuation multiples.
- EARNINGS QUALITY — The company beat analyst estimates in only 2 of the last 4 quarters, indicating inconsistent earnings predictability.
- TECHNICALS — RSI, MACD, and moving average data unavailable for this period; momentum cannot be independently confirmed.
- INSIDER — Insiders have net sold with 9 sells and 0 buys over the last 90 days, a cautious signal that may indicate management sentiment....
Stryker maintains strong profitability with a gross margin of 64.2% and a net margin of 13.2%, reflecting a high-value product mix typical of the medical technology sector. The balance sheet leans conservative with a debt/equity ratio of 0.71x, suggesting moderate leverage, while the current ratio of 1.89x indicates adequate short-term liquidity to cover liabilities. Return on equity stands at 15.1%, demonstrating efficient capital deployment and consistent shareholder value creation. Free cash flow data is unavailable in this dataset, limiting a full assessment of cash generation capacity. Overall, the financial profile supports reinvestment in R&D and acquisitions, with no immediate risk of dilution or dividend strain.
- VALUATION — P/E of 36.47x trades at a 66% premium to the sector average of 22x, pricing in high future growth expectations. - VALUATION — Price/Sales of 4.77x and Price/Book of 6.0x further elevate the stock above typical medical device valuation multiples. - EARNINGS QUALITY — The company beat analyst estimates in only 2 of the last 4 quarters, indicating inconsistent earnings predictability. - TECHNICALS — RSI, MACD, and moving average data unavailable for this period; momentum cannot be independently confirmed. - INSIDER — Insiders have net sold with 9 sells and 0 buys over the last 90 days, a cautious signal that may indicate management sentiment.
Unlock the full AI report
Full 8-section analysis includes:
Metric deep-dives